Chemaphor Inc. Gets Commercial, Healthcare and Animal Health Experience Boost: Amin Khalifa Joins the Board as Co-Chair

OTTAWA, CANADA--(Marketwire - June 23, 2010) - Further to its press release dated June 21, 2010, announcing the acquisition of rights to a new stem cell regenerative treatment for animals in Canada, Chemaphor Inc. (TSX VENTURE: CFR) announced today that Amin Khalifa has agreed to join Chemaphor's board of directors in the role of Co-Chair. In addition, Amin has signed a consulting agreement, under which Amin will assist Chemaphor with overall commercial plans, implementing sales strategies and connecting Chemaphor with other, commercially focused groups that are relevant to Chemaphor's growth strategy. Amin will share the role of Co-Chair with David Hankinson.

Mr. Khalifa currently sits on the Board of Directors of PetSmart, Inc. (Nasdaq: PETM) and has been the CFO of several public companies, including divisions of Monsanto, Aetna and Pepsico. He has extensive investment banking experience and has been actively involved in corporate and business development activity, having acted as principal in several large acquisitions.

Amin's prior experience includes:

--  CFO and EVP at Apria Healthcare Group, Inc. for three years, where he
identified and closed nearly one hundred acquisitions. Apria was
purchased by a private equity firm, The Blackstone Group L.P., for $1.7B
in 2008.

--  VP and CFO of Beckman Coulter (NYSE: BEC).

--  Positions held at Monsanto (NYSE: MON) as Chief Financial Officer of the
Agricultural Sector, as well as a Senior Vice President of Strategy and
Investor Relations for Aetna Inc. (NYSE: AET) and CFO of Aetna Health
Plans. Amin also previously worked as CFO and in business development
capacities during his fifteen year tenure at PepsiCo (NYSE: PEP).

David Hankinson, Co-Chair of Chemaphor, commented, "Having recently completed our first acquisition that confirms our focus on commercial opportunities within the animal health sector, we are delighted to attract to Chemaphor someone of Amin's very high caliber. Amin adds commercial, financial, corporate and business development experience, while having a specific understanding of our target markets. We welcome him to the board as Co-Chair and look forward to growing the company, together."

Mr. Khalifa added, "I have been fortunate to contribute to and experience growth from within large organizations and have had success. I have a strong interest in animal health and am convinced that I can translate the knowledge and experiences from the larger companies into successful growth at Chemaphor. I have reviewed Chemaphor's pipeline of opportunities and think that we have found a great fit."

The appointment of Mr. Khalifa, as with any director, remains subject to regulatory approval, including approval of the TSX Venture Exchange.

About Chemaphor

Chemaphor. a wellness company. is committed to developing and delivering natural health enhancer ("NHE") products to humans and animals to assist in optimizing health and daily quality of life. Chemaphor is advancing NHE product candidates for the food animal market, companion animal market and various, potential human applications. More information can be found at www.chemaphor.com.

Forward Looking Statements

This press release contains forward-looking statements regarding, among other things, Chemaphor's beliefs, plans, objectives, strategies, estimates, intentions and expectations. Actual results and events may differ materially from those included in, contemplated or implied by such forward looking statements for a variety of reasons. When used in this press release, the words "seek", "believe", "develop", "intends", "will", "may", "potential", "should" and similar expressions are intended to be among the statements that identify forward-looking statements. Forward-looking statements are subject to inherent risks and uncertainties including, but not limited to, market and general economic conditions, the availability to attract and retain key personnel, the availability and terms of financing, the scientific and commercial viability of planned products, changes in Chemaphor's relationship with its key suppliers and partners, competitive factors, changes in regulatory environments affecting Chemaphor's business, and the accuracy in management's assumptions. This list is not exhaustive of the factors that may affect any of Chemaphor's forward-looking statements. Investors and others should carefully consider these and other factors and not place undue reliance on these forward-looking statements. In addition, these forward-looking statements relate to the date on which they were made and Chemaphor disclaims and has no intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.